Of the 30 companies, three saw their stock prices increase, 26 saw their share prices decline, and one company's share price remained virtually flat month over month.

The ruling prevents the FDA rule on LDTs, which is opposed by much of the clinical lab industry and many segments of the broader healthcare industry, from going into effect.